GenoMe Diagnostics is a technology company.
GenoMe Diagnostics has raised $2.0M across 1 funding round.
GenoMe Diagnostics has raised $2.0M in total across 1 funding round.
GenoMe Diagnostics has raised $2.0M in total across 1 funding round.
GenoMe Diagnostics's investors include Deepbridge Capital.
GenoME Diagnostics is a biotechnology company developing OvaME, a blood-based diagnostic test for the earlier and more accurate detection of ovarian cancer.[1][2] As a spin-out from Queen’s University Belfast, it stems from a decade of research at the Patrick G Johnston Centre for Cancer Research and targets the critical need for improved ovarian cancer diagnostics, which often present late-stage due to ineffective screening methods.[1] The company's pipeline leverages cutting-edge technology for user-friendly, cost-effective biomarker discovery applicable to various diseases, serving clinicians, patients, and healthcare systems to enhance diagnostic pathways and outcomes.[1]
GenoME Diagnostics emerged from over 10 years of scientific research at the prestigious Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast, Northern Ireland, leading to its establishment as a university spin-out.[1][2][5] The company's registered office is at Qubis Ltd, 63 University Road, Belfast, reflecting its deep ties to the local innovation ecosystem.[5] Key early focus centered on translating academic breakthroughs into practical diagnostics, with OvaME as the lead product addressing ovarian cancer's diagnostic challenges—no specific founders are named in available records, but the venture pivoted from research to commercialization through institutional support.[1]
GenoME Diagnostics rides the wave of liquid biopsy advancements, a trend shifting cancer diagnostics from invasive tissue biopsies to accessible blood tests, fueled by progress in genomic sequencing and AI-driven biomarker analysis.[1] Timing aligns with rising demand for early-detection tools amid ovarian cancer's poor prognosis—over 90% of cases are diagnosed late—supported by market forces like aging populations, precision medicine initiatives, and regulatory pushes for non-invasive diagnostics.[1][2] It influences the ecosystem by exemplifying university spin-outs that bridge academia and biotech commercialization, particularly in the UK’s Northern Ireland hub, contributing to a global shift toward democratized, affordable oncology screening.[1][5]
GenoME Diagnostics is poised for clinical validation and partnerships to launch OvaME, potentially expanding its pipeline to other cancers via its versatile platform amid booming liquid biopsy markets projected to grow rapidly.[1] Trends like AI integration in diagnostics and payer emphasis on cost-effective early detection will propel it, evolving its role from ovarian cancer specialist to broader biomarker leader. This positions it to transform diagnostic pathways, echoing its research origins by delivering real-world impact in precision oncology.
GenoMe Diagnostics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $2.0M Seed | Deepbridge Capital |